Protagonist Therapeutics, Inc (PTGX) research
Protagonist Therapeutics, Inc- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $140.06
- As of
Protagonist Therapeutics, Inc (PTGX): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
As of . Source: SEC EDGAR filings for PTGX. Method and limitations.
Share the PTGX intelligence card
See the full PTGX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PTGX on one page. Preview it with sample data, then open it live with a free account.
Preview the PTGX dossierActive signals for PTGX
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +109% to PTGX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +406% to PTGX (2026Q2)
- highINSTITUTIONAL_SURGE
Bridgewater Associates, LP added +76% to PTGX (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 7.8%, EPS $2.29 vs $2.1238 estimate
- mediumNEW_POSITION
Bridgewater Associates, LP new position in PTGX
FREE, NO ACCOUNT
Every signal on PTGX, as it fires
You are seeing 5 of 9 signals recorded on PTGX since 2026-05-27.
The five above landed across 3 days. The other 4 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PTGX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Bridgewater Associates, LPCUSIP 74366E102 · 2026Q2 | $1.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PTGX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
PTGX against its peers
PTGX's operating margin of -343.6% ranks in the 22nd percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | PTGX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 46.0M USD | 502M USD | 25 | 17 |
| Operating margin | -343.6% | -31.3% | 22 | 15 |
| Net margin | -282.8% | -30.1% | 28 | 15 |
| Return on equity | -21.2% | -21.7% | 53 | 19 |
| P / E | n/a | 31.8x | n/a | 5 |
Peers (23): KYMR, CYTK, ARWR, IBRX, CRNX, CAI, NUVL, PCVX, TGTX, KRYS, ABVX, APGE, PRAX, IONS, SYRE, BMRN, MDGL, IMVT, RYTM, ALKS, BLTE, HALO, BBIO. Left out: SBMFF (no annual filing), BCHMY (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (PTGX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more PTGX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PTGXand get the insider, 13F, options, and confluence read in one view.